David Vulcano

Opinion: What Do the U.S. Election Results Mean to the Clinical Trials Industry?

Undoubtedly, the actions and inactions of the U.S. Congress have direct and indirect effects on the clinical trials industry. Also undoubtedly, anxiety is heightened at times after elections, especially when they result in changes of the administration. Times like these result in the struggle between those on their way out having last-minute opportunities to complete or build […]

Digital Technology

Survey: Digital Tech Use Up in Clinical Trials, But Concerns Remain

Nearly 98% of clinical research professionals plan to use digital technologies to collect patient data within the next five years, according to a study of 166 biopharma and life sciences industry researchers, executives, and technology/software professionals conducted by Validic. Broadly speaking, the study’s findings highlight how digital technologies will become significantly more important in the […]

Robert Romanchuk, Schulman IRB Vice Chair

Don’t Let an FDA 483 Become an Intimidating Warning Letter

After visiting clinical trial sites for more than 10 years, Schulman IRB Vice Chair Robert Romanchuk has a simple message: When you get a Food and Drug Administration (FDA) 483, consider your response to it seriously. It’s your best opportunity to address the situation and get back to business. It sounds like common sense, Romanchuk […]

Michael Causey, ACRP Editor-In-Chief

Douglas Bryant: An Appreciation

Douglas Bryant loved life. You could hear it in his voice. Douglas Bryant loved helping people. You could see it in his actions. I had the good fortune to work closely with Douglas for the past year when, as part of his volunteer contributions as the Public Member of ACRP’s Board of Trustees, he joined […]

David Vulcano

Analyst: Trump Means Change for Clinical Research Industry

Donald Trump is scheduled to become the 45th President of the United States on January 20. There will be many indirect and direct impacts on our industry as a result. Broadly speaking, we’re looking at two kinds of change: What the Trump Administration will change, and what changes industry will make in response. For example, […]